Trichostatin A (Synonyms: 曲古抑菌素A; TSA)

目錄號(hào): HY-15144 純度: 99.87%: FAQs
Data Sheet SDS COA 產(chǎn)品使用指南技術(shù)支持

Trichostatin A (TSA) 是有效的，特異的組蛋白去乙?；割愋?I 和 II (HDAC class I/II) 抑制劑，對(duì) HDAC 的 IC₅₀ 值為 1.8 nM。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Trichostatin A Chemical Structure

CAS No. : 58880-19-6

1. 客戶無需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2. 同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3. 試用裝只面向終端客戶。

規(guī)格	價(jià)格	是否有貨
10 mM * 1 mL in DMSO	￥1996	In-stock
2 mg	￥1200	In-stock
5 mg	￥2320	In-stock
10 mg	￥3760	In-stock
25 mg	現(xiàn)貨	詢價(jià)
50 mg		詢價(jià)
100 mg		詢價(jià)

or 大包裝詢價(jià)

* Please select Quantity before adding items.

Customer Review

Other Forms of Trichostatin A:

(S)-Trichostatin A 詢價(jià)

MCE 顧客使用本產(chǎn)品發(fā)表的 135 篇科研文獻(xiàn)

•Cell Discov. 2024 Sep 17;10(1):96. [Abstract]
•Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]
•Cell Metab. 2021 May 4;33(5):988-1000.e7. [Abstract]
•Nat Biomed Eng. 2018 Aug;2(8):578-588. [Abstract]
•Circ Res. 2022 Aug 19;131(5):456-472. [Abstract]
•Mil Med Res. 2022 Aug 23;9(1):46. [Abstract]

•Microbiome. 2023 Feb 23;11(1):31. [Abstract]
•Kidney Int. 2017 Sep;92(3):669-679. [Abstract]
•Adv Sci (Weinh). 2025 Jan 31:e2408845.
•Nat Commun. 2025 Jan 2;16(1):268. [Abstract]
•EMBO J. 2024 Sep 18. [Abstract]
•Adv Sci (Weinh). 2024 Jun 26:e2405332. [Abstract]
•J Exp Clin Cancer Res. 2024 May 30;43(1):152. [Abstract]
•Adv Sci (Weinh). 2023 Dec 25:e2303388. [Abstract]
•Adv Sci (Weinh). 2023 Oct 27:e2300698. [Abstract]
•Cell Death Differ. 2023 Oct 12. [Abstract]
•Cell Death Differ. 2023 Jun 15. [Abstract]
•J Hazard Mater. 2023 August 5, 455, 131540.
•J Exp Clin Cancer Res. 2023 Jan 5;42(1):5. [Abstract]
•Nat Commun. 2022 Oct 26;13(1):6350. [Abstract]
•Nat Commun. 2022 May 13;13(1):2672. [Abstract]
•EBioMedicine. 2022 Apr;78:103959. [Abstract]
•J Nanobiotechnology. 2022 Mar 9;20(1):120. [Abstract]
•J Exp Clin Cancer Res. 2022 Feb 2;41(1):47. [Abstract]
•Nat Commun. 2021 Sep 20;12(1):5548. [Abstract]
•Nat Commun. 2021 Jul 9;12(1):4227. [Abstract]
•Acta Pharm Sin B. 21 July 2021.
•Nat Commun. 2021 Feb 23;12(1):1237. [Abstract]
•Cancer Res. 2021 Jan 25;canres.2808.2020. [Abstract]
•Nucleic Acids Res. 2020 May 21;48(9):4858-4876. [Abstract]
•Theranostics. 2019 Apr 13;9(9):2424-2438. [Abstract]
•Cancer Lett. 2024 Jun 14:597:217005. [Abstract]
•Int J Biol Sci. 2024 Apr 29;20(7):2748-2762. [Abstract]
•Cell Death Dis. 2023 Nov 7;14(11):722. [Abstract]
•PLoS Biol. 2023 Jul 24;21(7):e3002199. [Abstract]
•Cancer Lett. 2022 Nov 30;216028. [Abstract]
•ACS Appl Mater Interfaces. 2022 Aug 1. [Abstract]
•Cell Death Dis. 2021 Oct 20;12(11):975. [Abstract]
•Cancer Lett. 2021 Jul 30;S0304-3835(21)00382-7. [Abstract]
•Cell Death Dis. 2021 May 18;12(6):501. [Abstract]
•Sci Total Environ. 2021, 147014.
•Int J Biol Sci. 2021 Apr 10;17(6):1555-1564. [Abstract]
•Acta Pharmacol Sin. 2021 Apr 6. [Abstract]
•Food Chem. 2021, 129696.
•Cell Death Dis. 2021 Jan 4;12(1):32. [Abstract]
•Pharmacol Res. 2020 Oct;160:105059. [Abstract]
•Cell Death Dis. 2018 Apr 27;9(5):497. [Abstract]
•Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):9967-76. [Abstract]
•Oncoimmunology. 2025 Dec;14(1):2460281.
•Biomed Pharmacother. 2024 Sep 23:180:117477. [Abstract]
•Oncogene. 2024 Sep 10. [Abstract]
•Int J Biol Macromol. 2024 Oct.
•Cell Rep. 2024 May 24;43(6):114272. [Abstract]
•Plant Physiol Biochem. 2024 May 6:211:108518. [Abstract]
•PLoS Pathog. 2024 Mar 12;20(3):e1012082. [Abstract]
•Phytomedicine. 2024 Feb 9, 155417.
•J Lipid Res. 2024 Jan 25:100510. [Abstract]
•Cell Rep. 2023 Oct 3;42(10):113211. [Abstract]
•Ecotoxicol Environ Saf. 2023 Jul 12;263:115197. [Abstract]
•EMBO Rep. 2023 Jun 12;e56437. [Abstract]
•Cell Rep. 2023 May 23;42(6):112550. [Abstract]
•Biomed Pharmacother. November 2022, 113843.
•Mol Cell Proteomics. 2022 Jun 7;100255. [Abstract]
•Cell Death Discov. 2022 May 17;8(1):265. [Abstract]
•J Agric Food Chem. 2021 Dec 23. [Abstract]
•Cell Death Discov. 2021 May 31;7(1):128. [Abstract]
•Biomed Pharmacother. 2021 Jan;133:111062. [Abstract]
•Hum Reprod. 2020 Mar 27;35(3):494-503. [Abstract]
•Immunology. 2020 Jun;160(2):183-197. [Abstract]
•Oncogene. 2020 Mar;39(11):2437-2449. [Abstract]
•Mol Ther Nucleic Acids. 2019 Dec 6;18:155-165. [Abstract]
•Cancer Immunol Immunother. 2025 Feb 1;74(3):81.
•Cell Signal. 2024 Sep 5:111386. [Abstract]
•Int J Mol Sci. 2024 Aug 24.
•iScience. 2024 Aug 21;27(9):110775. [Abstract]
•FASEB J. 2024 Aug 31;38(16):e23884. [Abstract]
•mSphere. 2024 Jul 30:e0040724. [Abstract]
•iScience. 2024 Jul 26.
•iScience. 2024 May 16.
•Int J Mol Sci. 2024 Mar 3, 25(5), 2947.
•Cells. 2023 Nov 29, 12(23), 2734.
•Int J Mol Sci. 2023 Sep 13, 24(18), 14049.
•Int J Mol Sci. 2023 Aug 31, 24(17), 13497.
•Sci Rep. 2023 Sep 11;13(1):15004. [Abstract]
•Nutrients. 2023 Jun 15, 15(12), 2760.
•J Ethnopharmacol. 2023 Feb 8;116240. [Abstract]
•Sci Rep. 2023 Jan 27;13(1):1483. [Abstract]
•Viruses. 2022, 14(7), 1485.
•J Immunol. 2022 Jul 18;ji2200078. [Abstract]
•Int J Mol Sci. 2022 Apr 2;23(7):3980. [Abstract]
•Appl Microbiol Biotechnol. 2022 Apr;106(8):3139-3152. [Abstract]
•Biology (Basel). 2022 Mar 22;11(4):483. [Abstract]
•Eur J Med Chem. 15 February 2022, 114115.
•Front Pharmacol. 2021 Jun 25;12:673366. [Abstract]
•J Cell Mol Med. 2021 Jul 18. [Abstract]
•Cancer Cell Int. 2021 Jun 5;21(1):291. [Abstract]
•Front Oncol. 2021 Mar 8;11:620154. [Abstract]
•Front Oncol. 2021; 11: 620154.
•FASEB J. 2021 Feb;35(2):e21316. [Abstract]
•J Proteome Res. 2021 Jan 1;20(1):960-971. [Abstract]
•Hum Cell. 2020 Oct;33(4):1006-1016. [Abstract]
•Cancer Cell Int. 2019 Nov 21;19:306. [Abstract]
•Int J Mol Med. 2020 Jan;45(1):210-222. [Abstract]
•J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
•J Cell Physiol. 2019 Dec;234(12):21988-21998. [Abstract]
•Int J Stem Cells. 2023 May 30;16(2):156-167. [Abstract]
•J Proteomics. 2024 May 24:105213. [Abstract]
•Heliyon. 2024 Feb 28.
•Arch Biochem Biophys. 2023 Dec 25:109878. [Abstract]
•Cancer Med. 2023 Aug 8. [Abstract]
•PeerJ. 2023 May 11.
•Microb Pathog. 2023 Mar 24;178:106078. [Abstract]
•J Proteomics. 2023 Mar 24;104889. [Abstract]
•Insects. 2023 Mar 23.
•Exp Cell Res. 27 October 2022, 113404.
•J Biol Chem. 2022 Aug 12;102374. [Abstract]
•Toxicol Appl Pharmacol. 2022 Jun 23;116140. [Abstract]
•Mol Immunol. 2021 Jun 1;136:55-64. [Abstract]
•Mol Med Rep. 2021 Apr 19.
•Gene. 2021 Feb 5;768:145308. [Abstract]
•J Dairy Sci. 2020 Dec;103(12):11636-11652. [Abstract]
•Theriogenology. 2020 Dec;158:233-238. [Abstract]
•Eur Rev Med Pharmaco. 2020 Apr;24(7):3935-3942. [Abstract]
•Dev Comp Immunol. 2020 Jun;107:103640. [Abstract]
•Insect Mol Biol. 2020 Feb;29(1):104-111. [Abstract]
•Biol Pharm Bull. 2024;47(10):1708-1716. [Abstract]
•Exp Brain Res. 2024 Jun 27. [Abstract]
•bioRxiv. 2024 July 27.
•SSRN. 2023 Oct 18.
•bioRxiv. 2023 Jun 6.
•bioRxiv. 2023 Jun 5.
•STAR Protoc. 2021, 100445.
•bioRxiv. 2020 Mar.
•bioRxiv. 2019 Apr.
•Fish Shellfish Immunol. 2019 Mar;86:549-558. [Abstract]

: Trichostatin A purchased from MCE. Usage Cited in: Nat Immunol. 2023 Jan;24(1):162-173. [Abstract]; A485 (10?μM; 24 h) leads to the downregulation of H3K9bhb and CPS1 in BHB-treated CD8⁺ T_M cells; however, the use of 3-TYP (10?μM; 24 h) or Trichostatin A (TSA; 5?nM; 24 h) result in the increase of H3K9bhb and CPS1.

: Trichostatin A purchased from MCE. Usage Cited in: Kidney Int. 2017 Sep;92(3):669-679. [Abstract]; PPARγ lysine 240 and 265 are essential for PPARγ acetylation-associated Klotho derepression. Cellular PPARγ acetylation assay. Human embryonic kidney 293 (HEK293) or human proximal tubular epithelial cells (HK2) cells are treated with trichostatin A (TSA) (100 ng/mL) for 4 hours then subjected to immunoprecipitation with anti-PPARγ antibody. Acetylated PPARγ is detected with a pan anti-acetyl-lysine (ac-K) antibody by Western blotting (WB). The cell lysates are also assayed for total PPARg, Klot

: Trichostatin A purchased from MCE. Usage Cited in: Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):9967-76. [Abstract]; SDL screens for TDP1 and validation pipeline. Acetylation levels after treatment with TSA in RMS (RH30) cells.

Trichostatin A 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

查看所有亞型

HDAC HDAC1 HDAC2 HDAC3 HDAC4 HDAC5 HDAC6 HDAC7 HDAC8 HDAC9 HDAC10 HDAC11 HD1 HD2

生物活性
實(shí)驗(yàn)參考方法
純度 & 產(chǎn)品資料
參考文獻(xiàn)

生物活性

Trichostatin A (TSA) is a potent and specific inhibitor of HDAC class I/II, with an IC₅₀ value of 1.8 nM for HDAC^[1].

IC₅₀ & Target^[1]

HDAC

1.8 nM (IC₅₀)

細(xì)胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.22 μM Compound: TSA	Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay Cytotoxicity against cisplatin resistant human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.25 μM Compound: TSA	Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in cisplatin resistant human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A2780	IC₅₀	0.29 μM Compound: TSA	Cytotoxicity against human A2780 cells after 72 hrs by MTT assay Cytotoxicity against human A2780 cells after 72 hrs by MTT assay	[PMID: 23252603]
A2780	IC₅₀	0.43 μM Compound: TSA	Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay Inhibition of HDAC in human A2780 cells after 18 hrs by fluorescence assay	[PMID: 23252603]
A-431	IC₅₀	0.18 μM Compound: TSA	Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A431 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
A549	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay Antiproliferative activity against human A549 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
A549	IC₅₀	0.05 μM Compound: TSA	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
A549	IC₅₀	0.08 μM Compound: TSA (1)	Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay	[PMID: 14667227]
A549	IC₅₀	0.16 μM Compound: TSA	Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
A549	IC₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human A549 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
A549	GI₅₀	80 nM Compound: TSA	Antiproliferative activity against human A549 cells after 72 hrs by MTS assay Antiproliferative activity against human A549 cells after 72 hrs by MTS assay	[PMID: 30004697]
BE(2)-C	IC₅₀	0.05 μM Compound: 1, TSA, trichostatin A	Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay Antiproliferative activity against human BE(2)-C cells after 72 hrs by Alamar blue assay	[PMID: 22932316]
Bel-7402	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay Antiproliferative activity against human Bel7402 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
BGC-823	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay Antiproliferative activity against human BGC823 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
BGC-823	IC₅₀	0.08 μM Compound: Trichostatin A	Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
BGC-823	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human BGC823 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
BT-474	IC₅₀	33.3 nM Compound: 8; TSA	Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human BT-474 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
BXPC-3	GI₅₀	100 nM Compound: TSA	Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay Antiproliferative activity against human BxPC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
DMS-53	IC₅₀	25 nM Compound: Trichostatin A	Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay Cytostatic activity against human DMS53 cells assessed as inhibition of cell proliferation after 2 days by MTT assay	[PMID: 21504214]
DU-145	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay Antiproliferative activity against human DU145 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
DU-145	IC₅₀	0.2 μM Compound: TSA	Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce DU145 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
HCT-116	IC₅₀	< 0.05 μM Compound: TSA	Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce HCT 116 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
HCT-116	IC₅₀	0.013 μM Compound: 1	Concentration required to inhibit the HCT116 cell growth by 50%. Concentration required to inhibit the HCT116 cell growth by 50%.	[PMID: 11831887]
HCT-116	IC₅₀	0.043 μM Compound: 1, TSA	Growth inhibition of human HCT116 cells after 48 hrs by SRB assay Growth inhibition of human HCT116 cells after 48 hrs by SRB assay	[PMID: 21073160]
HCT-116	IC₅₀	0.8 μM Compound: TSA	Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay Cytotoxicity against human HCT116 cells after 3 days by WST-1 assay	[PMID: 20452226]
HCT-116	EC₅₀	1 μM Compound: 1 (trichostatin A)	In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay In vitro antiproliferative activity against human colon cancer HCT 116 cells determined by MMT assay	[PMID: 11597413]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HCT-116 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
HCT-116	GI₅₀	35 nM Compound: TSA	Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTS assay	[PMID: 30004697]
HEK293	IC₅₀	0.16 μM Compound: 5	Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay Cytotoxicity against human HEK293 cells after 96 hrs by MTT assay	[PMID: 25556102]
HeLa	IC₅₀	0.0011 μM Compound: TSA	Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay Inhibition of HDAC2 in human HeLa cell nuclear extracts in presence of dithiothreitol by HDAC fluorescent assay	[PMID: 22465091]
HeLa	EC₅₀	0.0052 μM Compound: TSA	Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA Inhibition of HDAC6 in human HeLa cells assessed as inhibition of tubulin deacetylation incubated for overnight by cELISA	[PMID: 26611919]
HeLa	IC₅₀	0.0075 μM Compound: Trichostatin A	Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell extract after 15 mins by fluorescence assay	[PMID: 25455492]
HeLa	IC₅₀	0.02 μM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extract assessed as inhibition of histone H4 deacetylation after 15 mins by fluorescence assay	[PMID: 20381359]
HeLa	IC₅₀	0.09 μM Compound: TSA	Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay Antiproliferative activity against human HeLa cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HeLa	IC₅₀	0.1 μM Compound: Trichostatin A	Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HeLa	IC₅₀	0.11 μM Compound: TSA	Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HeLa	IC₅₀	0.3 μM Compound: Trichostatin A	Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay Inhibition of HDAC from human HeLa cells by fluorogenic enzyme assay	[PMID: 19457659]
HeLa	IC₅₀	0.85 μM Compound: 5	Cytotoxicity against human HeLa cells after 96 hrs by MTT assay Cytotoxicity against human HeLa cells after 96 hrs by MTT assay	[PMID: 25556102]
HeLa	IC₅₀	1.42 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay Inhibition of HDAC in human HeLa cell nuclear extract using BML-KI104 Fluor de Lys as substrate by fluorescence-based assay	[PMID: 26588603]
HeLa	IC₅₀	12 nM Compound: TSA	Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay Inhibition of HDAC isolated from human HeLa cells by fluorimetric assay	10.1039/C4MD00211C
HeLa	IC₅₀	28.9 nM Compound: TSA	Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay Inhibition of human HDAC in human HeLa cell nuclear extract after 15 mins by colorimetric assay	[PMID: 20167479]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay Inhibition of HDAC in human HeLa cells using Ac-Arg-Gly-Lys(Ac)-AMC as fluorescent substrate after 20 mins by fluorescence assay	[PMID: 21621883]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell nuclear extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	3 nM Compound: TSA	Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay Inhibition of HDAC in human HeLa cell cytosolic extract after 30 mins by fluorimetric assay	[PMID: 19705846]
HeLa	IC₅₀	39 nM Compound: TSA	Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay	[PMID: 30245394]
HeLa	IC₅₀	41 nM Compound: TSA	Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay Inhibition of Histone deacetylase in HeLa cell nuclear extracts by fluorescence-based assay	[PMID: 17419603]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay Inhibition of HDAC in human HeLa cell nuclear extracts after 15 mins by fluorescence assay	[PMID: 19914074]
HeLa	IC₅₀	5 nM Compound: TSA	Inhibition of human HDAC in HeLa cells by flour de lys assay Inhibition of human HDAC in HeLa cells by flour de lys assay	[PMID: 18397827]
HepG2	EC₅₀	0.38 μM Compound: 5	Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay Up-regulation of transcriptional activity of human CLA-1 promoter region -1055 to -62bp transfected in HepG2 cells by luciferase reporter gene assay	[PMID: 25556102]
HepG2	IC₅₀	0.96 μM Compound: 5	Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay Cytotoxicity against human HepG2 cells after 96 hrs by MTT assay	[PMID: 25556102]
HL-60	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
HL-60	IC₅₀	0.08 μM Compound: TSA	Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HL60 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HL-60	GI₅₀	0.59 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay Antiproliferative activity against human HL60 cells after 24 hrs by MTT assay	[PMID: 29454918]
HMEC	IC₅₀	1.6 μM Compound: TSA	Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay Inhibitory concentration required to reduce normal human epithelial cell line (HMEC), growth by 50% in MTT assay	[PMID: 12061890]
HT-1080	IC₅₀	0.08 μM Compound: TSA	Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HT1080 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
HT-29	IC₅₀	3.8 nM Compound: TSA	Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control Antiproliferative activity against human HT-29 cells in presence of isoCA-4 after 72 hrs by MTS assay relative to control	[PMID: 30004697]
HT-29	GI₅₀	34.1 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay	[PMID: 30004697]
HT-29	IC₅₀	55 nM Compound: TSA	Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human HT-29 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
Huh-7	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human HuH7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
Huh-7	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
Huh-7	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay Inhibition of IL-1-beta-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of IL1-beta challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay Inhibition of HOSCN-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of HOSCN challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	20 nM Compound: TSA, trichostatin A	Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay Inhibition of LPS-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of LPS challenge by one stage clotting assay	[PMID: 17675290]
HUVEC	IC₅₀	30 nM Compound: TSA, trichostatin A	Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay Inhibition of TNF-alpha-induced tissue factor activity in HUVEC preincubated for 4 hrs assessed after 4 hrs of TNFalpha challenge by one stage clotting assay	[PMID: 17675290]
K562	IC₅₀	0.12 μM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
K562	IC₅₀	0.16 μM Compound: Trichostatin A	Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
K562	IC₅₀	0.41 μM Compound: TSA	Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human K562 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
K562	IC₅₀	260 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human K562 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
K562	GI₅₀	262 nM Compound: TSA	Antiproliferative activity against human K562 cells after 72 hrs by MTS assay Antiproliferative activity against human K562 cells after 72 hrs by MTS assay	[PMID: 30004697]
K562	IC₅₀	560 nM Compound: TSA	Antiproliferative activity against human K562 cells after 48 hrs by MTT assay Antiproliferative activity against human K562 cells after 48 hrs by MTT assay	[PMID: 30245394]
K562	IC₅₀	90 nM Compound: TSA	Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay Antiproliferative activity against imatinib-resistant human K562 cells over expressing MDR1 after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
K-562R	GI₅₀	88 nM Compound: TSA	Antiproliferative activity against human K562R cells after 72 hrs by MTS assay Antiproliferative activity against human K562R cells after 72 hrs by MTS assay	[PMID: 30004697]
L02	IC₅₀	0.21 μM Compound: 5	Cytotoxicity against human LO2 cells after 96 hrs by MTT assay Cytotoxicity against human LO2 cells after 96 hrs by MTT assay	[PMID: 25556102]
MCF7	IC₅₀	0.06 μM Compound: Trichostatin A	Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MCF7	IC₅₀	0.06 μM Compound: TSA	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
MCF7	IC₅₀	0.07 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MCF7 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MCF7	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MCF-7 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MCF7	IC₅₀	1.7 μM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 22465091]
MCF7	IC₅₀	141 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 30245394]
MCF7	IC₅₀	27.7 nM Compound: 8; TSA	Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition by SRB assay	[PMID: 34826681]
MCF7	GI₅₀	45 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay	[PMID: 30004697]
MCF7	IC₅₀	54 nM Compound: TSA	Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MCF7 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-231	IC₅₀	0.09 μM Compound: TSA	Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce MDAmb 231 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
MDA-MB-231	IC₅₀	91 nM Compound: TSA	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MDA-MB-435	GI₅₀	1.78 μM Compound: TRICHOSTATIN A	Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay Antiproliferative activity against human MDA-MB-435 cells after 24 hrs by MTT assay	[PMID: 29454918]
MDCK	IC₅₀	0.008 μM Compound: Trichostatin A	Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay Antiviral activity against Influenza A virus A/Hong Kong/8/68 H3N2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by CCK8 assay	10.1039/C3MD00371J
MIA PaCa-2	IC₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human MIA PaCa-2 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
MIA PaCa-2	GI₅₀	200 nM Compound: TSA	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by MTS assay	[PMID: 30004697]
MOLT-4	IC₅₀	0.02 μM Compound: TSA	Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay Antiproliferative activity against human MOLT4 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
MOLT-4	IC₅₀	0.03 μM Compound: Trichostatin A	Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
MOLT-4	IC₅₀	0.03 μM Compound: TSA	Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human MOLT4 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H1975	IC₅₀	0.09 μM Compound: Trichostatin A	Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
NCI-H1975	IC₅₀	0.21 μM Compound: TSA	Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
NCI-H446	IC₅₀	0.08 μM Compound: TSA	Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce H446 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
NCI-H460	IC₅₀	0.1 μM Compound: 1, TSA	Growth inhibition of human H460 cells after 48 hrs by SRB assay Growth inhibition of human H460 cells after 48 hrs by SRB assay	[PMID: 21073160]
NCI-H661	IC₅₀	0.085 μM Compound: 7, TSA	Antiproliferative activity against H661 cells after 48 hrs by XTT assay Antiproliferative activity against H661 cells after 48 hrs by XTT assay	[PMID: 17624773]
NCI-H661	IC₅₀	0.085 μM Compound: 1 (TSA)	Antiproliferative activity against H661 cells after 48 hrs Antiproliferative activity against H661 cells after 48 hrs	[PMID: 17897824]
NCI-H661	IC₅₀	0.1 μM Compound: 1, TSA	Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay Antiproliferative activity against human NCI-H661 cells after 48 hrs by XTT assay	[PMID: 19385600]
NCI-N87	IC₅₀	0.06 μM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
NCI-N87	IC₅₀	58 nM Compound: TSA	Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human NCI-N87 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
NIH3T3	IC₅₀	0.006 μM Compound: Trichostatin A	Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay Inhibition of HDAC1 in human NIH3T3 cells by radiometric histone deacetylation assay	[PMID: 19457659]
PANC-1	IC₅₀	0.1 μM Compound: TSA	Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
PC-3	GI₅₀	387 nM Compound: TSA	Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay	[PMID: 30004697]
Sf21	IC₅₀	0.032 μM Compound: TSA	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay	[PMID: 30448419]
Sf21	IC₅₀	1.58 x 10^-2 μM Compound: Trichostatin A	Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay Inhibition of recombinant full length human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 cells using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorimetric assay	[PMID: 31838329]
Sf21	IC₅₀	17.9 nM Compound: Trichostatin A	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	[PMID: 31924504]
Sf21	IC₅₀	25 nM Compound: TSA	Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay Inhibition of recombinant human GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by fluorescence assay	[PMID: 32212730]
Sf21	IC₅₀	3.95 x 10^-2 μM Compound: Trichostatin A	Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay Inhibition of recombinant human C-terminal GST-tagged HDAC2 (1 to 488 residues) expressed in baculovirus infected sf21 cells using RHK-K(Ac)-AMC as substrate after 60 mins by fluorimetry assay	[PMID: 31838329]
Sf21	IC₅₀	6.574 nM Compound: TSA	Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay Inhibition of full length human recombinant C-terminal FLAG-His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 cells using RHK-K(Ac)-AMC as substrate incubated for 60 mins by fluorescence assay	[PMID: 27060764]
Sf21	IC₅₀	9 nM Compound: TSA	Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by flu Inhibition of full length recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in baculovirus infected Sf21 insect cells using fluorogenic peptide p53 residues 379-382 (RHKK(Ac)AMC) as substrate measured after 1 to 2 hrs by flu	[PMID: 32212730]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC4 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 1.5 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	> 1 μM Compound: TSA	Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant human HDAC9 (604-1066 residues) expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.000681 μM Compound: TSA	Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC1 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.00161 μM Compound: TSA	Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC10 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.002 μM Compound: TSA	Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s Inhibition of recombinant N-terminal GST-tagged human HDAC6 (1 to 1215 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mins followed by s	[PMID: 31414801]
Sf9	IC₅₀	0.00274 μM Compound: TSA	Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC2 expressed in baculovirus infected Sf9 cells using FAM-RHKK-Ac as substrate incubated for 17 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.009 μM Compound: TSA	Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi Inhibition of recombinant full length C-terminal His/FLAG tagged human HDAC1 (1 to 482 residues) expressed in baculovirus infected sf9 insect cells using p53 (379 to 382 residues) derived fluorogenic peptide RHKKAc as substrate preincubated for 5 to 10 mi	[PMID: 31414801]
Sf9	IC₅₀	0.482 μM Compound: TSA	Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC7 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.776 μM Compound: TSA	Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay Inhibition of recombinant full length human HDAC5 expressed in baculovirus infected Sf9 cells using FAM-RHKK-TFAc as substrate incubated for 3 hrs by electrophoretic mobility shift assay	[PMID: 31938464]
Sf9	IC₅₀	0.9 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	1.2 nM Compound: TSA	Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	1.716 nM Compound: TSA	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate incubated for 90 mins by fluorescence assay	[PMID: 27060764]
Sf9	IC₅₀	129 nM Compound: TSA	Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	15.7 nM Compound: Trichostatin A	Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
Sf9	IC₅₀	17.3 nM Compound: TSA	Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	5 nM Compound: TSA	Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	9 nM Compound: TSA	Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	960 nM Compound: 1, TSA	Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay Inhibition of N terminal hexahistidine-tagged human HDAC8 expressed in Sf9 cells after 1 hr by fluorescence assay	[PMID: 21723733]
SGC-7901	IC₅₀	0.03 μM Compound: TSA	Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SGC7901 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SH-SY5Y	IC₅₀	18.8 nM Compound: Trichostatin A	Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	7.8 nM Compound: Trichostatin A	Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	9.1 nM Compound: Trichostatin A	Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SK-BR-3	IC₅₀	0.05 μM Compound: TSA	Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay Antiproliferative activity against human SK-BR-3 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
SK-OV-3	IC₅₀	100 nM Compound: TSA	Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay Antiproliferative activity against human SK-OV-3 cells after 72 hrs by CellTiter Glo assay	[PMID: 35797900]
SW48	IC₅₀	0.1 μM Compound: TSA	Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce SW48 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
T-24	IC₅₀	0.15 μM Compound: TSA	Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay Inhibitory concentration required to reduce T24 tumor cell growth by 50% in MTT assay	[PMID: 12061890]
T47D	IC₅₀	26.4 nM Compound: 8; TSA	Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method Antiproliferative activity against human T47D cells assessed as cell growth inhibition by burton method	[PMID: 34826681]
U-251	IC₅₀	611.2 nM Compound: 2	Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay Inhibition of SAP130 in VEGF-stimulated human U251 cells by PLAP reporter gene assay	[PMID: 17643112]
U2OS	IC₅₀	14.93 μM Compound: 5	Cytotoxicity against human U2OS cells after 96 hrs by MTT assay Cytotoxicity against human U2OS cells after 96 hrs by MTT assay	[PMID: 25556102]
U-87MG ATCC	GI₅₀	1038 nM Compound: TSA	Antiproliferative activity against human U87 cells after 72 hrs by MTS assay Antiproliferative activity against human U87 cells after 72 hrs by MTS assay	[PMID: 30004697]
U-937	IC₅₀	0.04 μM Compound: TSA	Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay Antiproliferative activity against human U937 cells after 72 hrs by CCK8 assay	[PMID: 27427973]
U-937	IC₅₀	0.05 μM Compound: Trichostatin A	Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as cell viability after 72 hrs by CCK8 assay	10.1039/C3MD00371J
U-937	IC₅₀	0.1 μM Compound: TSA	Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay Cytotoxicity against human U937 cells assessed as reduction in cell viability after 72 hrs by CCK8 assay	[PMID: 24960627]
Vero	IC₅₀	0.6 μM Compound: Trichostatin A	Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay Antiviral activity against EV71 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathic effect after 72 to 96 hrs by CCK8 assay	10.1039/C3MD00371J
Vero	IC₅₀	41.2 ng/mL Compound: TSA	Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	49.5 ng/mL Compound: TSA	Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 infected in African green monkey (Cercopithecus aethiops) Vero cells assessed as parasite LDH activity after 72 hrs by Malstat reagent method	[PMID: 19914074]
Vero	IC₅₀	95 ng/mL Compound: TSA	Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay Cytotoxicity against african green monkey Vero cells after 1 to 2 days by neutral red assay	[PMID: 19914074]

體外研究
(In Vitro)

Trichostatin A 是一種有效且特異性的 HDAC I/II 類抑制劑，對(duì) HDAC 的 IC₅₀ 值為 1.8 nM。Trichostatin A (TSA) 抑制八種乳腺癌細(xì)胞系的增殖，IC₅₀ 為 124.4±120.4 nM (26.4-308.1 nM)。Trichostatin A 的 HDAC 抑制活性在所有細(xì)胞系中相似，平均 IC₅₀ 為 2.4±0.5 nM (范圍，1.5-2.9 nM)^[1]。Trichostatin A (330 nM) 增加人子宮肌層細(xì)胞中 Gαs 蛋白的表達(dá)，但不增加 Gαs mRNA 水平^[2]。Trichostatin A (20-75 nM) 對(duì)脂肪來源的干細(xì)胞 (ADSCs) 具有最小的細(xì)胞毒性，并增強(qiáng) ADSCs 的成骨分化能力^[3]。此外，Trichostatin A (0、10、100、500 nM) 劑量依賴性地降低 HDAC I/II 類活性^[4]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

在使用 N-甲基-N-亞硝基脲致癌物誘導(dǎo)的大鼠乳腺的隨機(jī)對(duì)照功效研究中，Trichostatin A (500 μg/kg，皮下注射) 顯示出抗腫瘤活性，而皮下注射劑量高達(dá) 5 mg/kg 時(shí)不會(huì)引起任何可測(cè)量的毒性癌模型^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

302.37

Formula

C₁₇H₂₂N₂O₃

CAS 號(hào)

58880-19-6

性狀

固體

顏色

White to light yellow

中文名稱

曲古抑菌素A

結(jié)構(gòu)分類

Ketones, Aldehydes, Acids

初始來源

內(nèi)源性代謝物

運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.

儲(chǔ)存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

溶解性數(shù)據(jù)

細(xì)胞實(shí)驗(yàn)：

DMSO 中的溶解度 : 50 mg/mL (165.36 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開封的 DMSO)

Methanol 中的溶解度 : 2 mg/mL (6.61 mM; 超聲助溶)

配制儲(chǔ)備液

濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg

1 mM	3.3072 mL	16.5360 mL	33.0721 mL
5 mM	0.6614 mL	3.3072 mL	6.6144 mL
10 mM	0.3307 mL	1.6536 mL	3.3072 mL

查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 2 years; -20°C, 1 year。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用。

摩爾計(jì)算器
稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

濃度 _(start)

體積 _(start)

濃度 _(final)

體積 _(final)

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥方式選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的方式助溶

方案一

請(qǐng)依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.27 mM); 懸濁液; 超聲助溶

此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水定容至 1 mL。
生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
方案二

請(qǐng)依序添加每種溶劑： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

此方案可獲得 ≥ 2.5 mg/mL（飽和度未知）的澄清溶液。
以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液中，混合均勻。
2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
方案三

請(qǐng)依序添加每種溶劑： 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: 2.5 mg/mL (8.27 mM); 懸濁液; 超聲助溶
方案四

請(qǐng)依序添加每種溶劑： 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.27 mM); 澄清溶液

動(dòng)物溶解方案計(jì)算器

請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只

由于實(shí)驗(yàn)過程有損耗，建議您多配一只動(dòng)物的量

請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：

DMSO +

Tween-80 +

Saline

如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。

方案所需 助溶劑 包括：DMSO，，均可在 MCE 網(wǎng)站選購(gòu)。，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。

計(jì)算結(jié)果

工作液所需濃度 : mg/mL

儲(chǔ)備液配制方法 : mg 藥物溶于 μL DMSO（母液濃度為 mg/mL）。

您所需的儲(chǔ)備液濃度超過該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。

動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。

連續(xù)給藥周期超過半月以上，請(qǐng)謹(jǐn)慎選擇該方案。

請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱（超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。

純度 & 產(chǎn)品資料

純度: 99.91%

選擇批次：

Data Sheet (644 KB) SDS (393 KB)

COA (188 KB) HNMR (263 KB) LCMS (265 KB) OR (170 KB) 元素分析報(bào)告 (204 KB)

產(chǎn)品使用指南 (1538 KB)

參考文獻(xiàn)

[1]. Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. [Content Brief]

[2]. Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. [Content Brief]

[3]. Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. [Content Brief]

[4]. Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. [Content Brief]

Cell Assay ^[3]	Cells are cultured in a 96-well plate at 1×10³ cells per well with 100 μL complete DMEM in the presence or absence of a HDAC inhibitor Trichostatin A for 72 h. Cytotoxicity is measured by performing WST-8 assay using a CCK-8 cell proliferation kit. The 450 nm absorbance is measured with a microplate reader. All experiments are carried out in triplicate and 3 independent experiments are performed^[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	Rats^[1] Twelve rats are randomized to receive 500 μg/kg Trichostatin A in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection twice weekly for 4 weeks. In subsequent studies, 30 rats are randomized to receive Trichostatin A 500 μg/kg in 50 μL DMSO, or 50 μL DMSO as vehicle control, by s.c. injection daily for 4 weeks. Weekly tumor measurements, estimated tumor volumes, and body mass are recorded for each animal. Animals are sacrificed at the end of the 4-week study period; palpable tumors are resected and immediately snap-frozen in liquid nitrogen. Animals with tumors <2 cm in diameter or ulcerating tumors are withdrawn from study^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
參考文獻(xiàn)	[1]. Vigushin DM et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001 Apr;7(4):971-6. [Content Brief] [2]. Karolczak-Bayatti M, et al. Expression of the GTP-Binding Protein Gαs in Human Myometrial Cells is Regulated by Ubiquitination and Protein Degradation: Involvement of Proteasomal Inhibition by Trichostatin A.,Reprod Sci. 2012 Aug 8. [Content Brief] [3]. Hu X, et al. Histone deacetylase inhibitor trichostatin A promotes the osteogenic differentiation of rat adipose-derived stem cells by altering the epigenetic modifications on Runx2 promoter in a BMP signaling-dependent manner.,Stem Cells Dev. 2012 Aug 8. [Content Brief] [4]. Azechi T, et al. Trichostatin A, an HDAC class I/II inhibitor, promotes Pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase. J Atheroscler Thromb. 2013;20(6):538-47. [Content Brief]

Trichostatin A 相關(guān)分類

完整儲(chǔ)備液配制表

可選溶劑	濃度溶劑體積質(zhì)量	1 mg	5 mg	10 mg	25 mg

Methanol / DMSO	1 mM	3.3072 mL	16.5360 mL	33.0721 mL	82.6802 mL
Methanol / DMSO	5 mM	0.6614 mL	3.3072 mL	6.6144 mL	16.5360 mL
DMSO	10 mM	0.3307 mL	1.6536 mL	3.3072 mL	8.2680 mL
	15 mM	0.2205 mL	1.1024 mL	2.2048 mL	5.5120 mL
	20 mM	0.1654 mL	0.8268 mL	1.6536 mL	4.1340 mL
	25 mM	0.1323 mL	0.6614 mL	1.3229 mL	3.3072 mL
	30 mM	0.1102 mL	0.5512 mL	1.1024 mL	2.7560 mL
	40 mM	0.0827 mL	0.4134 mL	0.8268 mL	2.0670 mL
	50 mM	0.0661 mL	0.3307 mL	0.6614 mL	1.6536 mL
	60 mM	0.0551 mL	0.2756 mL	0.5512 mL	1.3780 mL
	80 mM	0.0413 mL	0.2067 mL	0.4134 mL	1.0335 mL
	100 mM	0.0331 mL	0.1654 mL	0.3307 mL	0.8268 mL

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Trichostatin A58880-19-6TSA曲古抑菌素AOrganoidHDACHistone deacetylasesInhibitorinhibitorinhibit

產(chǎn)品名稱：			* 需求量：
* 客戶姓名：			* Email：
* 電話：			* 公司或機(jī)構(gòu)名稱：
留言給我們：

產(chǎn)品名稱：			* Lot #：
* 客戶姓名：			* Email：
電話：			* 部門：
* 公司或機(jī)構(gòu)名稱：
留言給我們：

MedChemExpress (MCE) 只為有資質(zhì)的科研機(jī)構(gòu)、醫(yī)藥企業(yè)基于科學(xué)研究或藥證申報(bào)的用途提供醫(yī)藥研發(fā)服務(wù)，不為任何個(gè)人或者非科研性質(zhì)的、非用于藥證申報(bào)使用等其他用途提供服務(wù)。	站點(diǎn)地圖隱私聲明
滬ICP備15051369號(hào)-4 上海工商滬公網(wǎng)安備31011502019417 滬(浦)應(yīng)急管危經(jīng)許[2021]201709(QFYS) 營(yíng)業(yè)執(zhí)照（三證合一）
Copyright ? 2013-2025 MedChemExpress. All Rights Reserved.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Trichostatin A (Synonyms: 曲古抑菌素A; TSA)

Customer Review

Other Forms of Trichostatin A:

MCE 顧客使用本產(chǎn)品發(fā)表的 135 篇科研文獻(xiàn)

Trichostatin A 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

摩爾計(jì)算器

稀釋計(jì)算器

Trichostatin A 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
郵箱 *

Sorry, but the email address you supplied was invalid.

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Trichostatin A (Synonyms: 曲古抑菌素A; TSA)

Customer Review

Other Forms of Trichostatin A:

Trichostatin A 相關(guān)抗體

MCE 顧客使用本產(chǎn)品發(fā)表的 135 篇科研文獻(xiàn)

Trichostatin A 相關(guān)產(chǎn)品

•相關(guān)化合物庫(kù):

•同靶點(diǎn)產(chǎn)品:

•同靶點(diǎn)蛋白產(chǎn)品:

查看 HDAC 亞型特異性產(chǎn)品:

生物活性

實(shí)驗(yàn)參考方法

純度 & 產(chǎn)品資料

參考文獻(xiàn)

Trichostatin A 相關(guān)抗體:

摩爾計(jì)算器

稀釋計(jì)算器

Trichostatin A 相關(guān)分類

完整儲(chǔ)備液配制表

Keywords:

您最近查看的產(chǎn)品:

Request for HNMR Report

Request for HNMR Report

熱門區(qū)域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z